Skip to main content

Uterine papillary serous carcinoma: State of the state

Current Oncology Reports volume 10, pages 505–511 (2008)Cite this article

Abstract

Uterine papillary serous carcinoma (UPSC) is an aggressive form of endometrial cancer that is likely to present with deep myometrial invasion and lymph vascular involvement. By the time most affected women are diagnosed, the UPSC has spread outside the uterus. Because many reports include patients who are not completely staged, the risk of recurrence in stage I patients has likely been overestimated. Recently, several large series of well-staged patients have demonstrated that survival in stage I patients is similar to that of poorly differentiated endometrioid tumors. Because of the high risk of extrauterine spread, all patients with UPSC should have an extended surgical staging procedure, including lymphadenectomy and omentectomy. Chemotherapy with or without local or regional radiation is probably the most effective adjuvant therapy in both early and advanced disease. Because patients with stage I UPSC are still at significant risk of recurrence, adjuvant therapy is often recommended for all patients. It has been difficult to conduct prospective randomized trials for patients with UPSC because of the rare nature of these cancers.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References and Recommended Reading

  1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43–66.

    PubMed  Article  Google Scholar 

  2. Hendrickson M, Ross J, Eifel P, et al.: Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982, 6:93–108.

    PubMed  CAS  Google Scholar 

  3. Gusberg SB: Precursors of corpus carcinoma: estrogens and adenomatous hyperplasia. 1947. CA Cancer J Clin 1989, 39:179–192.

    PubMed  Article  CAS  Google Scholar 

  4. Way S: The aetiology of carcinoma of the body of the uterus. J Obstet Gynaecol Brit Emp 1954, 1:46–58.

    Google Scholar 

  5. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10–17.

    PubMed  Article  CAS  Google Scholar 

  6. Mutter GL, Baak JP, Fitzgerald JT, et al.: Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 2001, 83:177–185.

    PubMed  Article  CAS  Google Scholar 

  7. Zheng W, Liang SX, Yu H, et al.: Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004, 12:207–223.

    PubMed  Article  Google Scholar 

  8. Hamilton CA, Cheung MK, Osann K, et al.: Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006, 94:642–646.

    PubMed  CAS  Google Scholar 

  9. Sherman ME, Bitterman P, Rosenshein NB, et al.: Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992, 16:600–610.

    PubMed  CAS  Article  Google Scholar 

  10. Ambros RA, Sherman ME, Zahn CM, et al.: Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995, 26:1260–1267.

    PubMed  Article  CAS  Google Scholar 

  11. Slomovitz BM, Burke TW, Eifel PJ, et al.: Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003, 91:463–469.

    PubMed  Article  Google Scholar 

  12. Zheng W, Liang SX, Yi X, et al.: Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma. Int J Gynecol Pathol 2007, 26:38–52.

    PubMed  Article  CAS  Google Scholar 

  13. Goff BA, Kato D, Schmidt RA, et al.: Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994, 54:264–268.

    PubMed  Article  CAS  Google Scholar 

  14. Sherman ME, Bur ME, Kurman RJ: p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995, 26:1268–1274.

    PubMed  Article  CAS  Google Scholar 

  15. Carcangiu ML, Tan LK, Chambers JT: Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997, 21:1507–1514.

    PubMed  Article  CAS  Google Scholar 

  16. Bur ME, Perlman C, Edelmann L, et al.: p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992, 98:81–87.

    PubMed  CAS  Google Scholar 

  17. Santin AD, Zhan F, Cane S, et al.: Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 2005, 92:1561–1573.

    PubMed  Article  CAS  Google Scholar 

  18. Slomovitz BM, Broaddus RR, Burke TW, et al.: Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004, 22:3126–3132.

    PubMed  Article  CAS  Google Scholar 

  19. Kelly MG, O’Malley DM, Hui P, et al.: Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005, 98:353–359.

    PubMed  Article  CAS  Google Scholar 

  20. Geisler JP, Geisler HE, Melton ME, Wiemann MC: What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 1999, 74:465–467.

    PubMed  Article  CAS  Google Scholar 

  21. Chan JK, Loizzi V, Youssef M, et al.: Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003, 90:181–185.

    PubMed  Article  Google Scholar 

  22. Creasman WT, Kohler MF, Odicino F, et al.: Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol 2004, 95:593–596.

    PubMed  Article  Google Scholar 

  23. McMeekin DS, Filiaci VL, Thigpen JT, et al.: The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in fir-stline chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007, 106:16–22.

    PubMed  Article  Google Scholar 

  24. Keys HM, Roberts JA, Brunetto VL, et al.: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 92:744–751. [Published erratum appears in Gynecol Oncol 2004, 94:241–242.]

    PubMed  Article  Google Scholar 

  25. Havrilesky LJ, Secord AA, Bae-Jump V, et al.: Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007, 105:677–682.

    PubMed  Article  Google Scholar 

  26. Goldberg H, Miller RC, Abdah-Bortnyak R, et al.: Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN). Gynecol Oncol 2008, 108:298–305.

    PubMed  Article  Google Scholar 

  27. Huh WK, Powell M, Leath CA 3rd, et al.: Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003, 91:470–475.

    PubMed  Article  Google Scholar 

  28. Hogberg T, Rosenberg P, Kristensen G, et al.: A randomized phase-III study on adjuvant treatment with radiation ± chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991 [abstract]). J Clin Oncol 2007, 25:5503.

    Google Scholar 

  29. Randall ME, Filiaci VL, Muss H, et al.: Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006, 24:36–44.

    PubMed  Article  CAS  Google Scholar 

  30. Bristow RE, Duska LR, Montz FJ: The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001, 81:92–99.

    PubMed  Article  CAS  Google Scholar 

  31. Smith RS, Kapp DS, Chen Q, Teng NN: Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. Int J Radiat Oncol Biol Phys 2000, 48:767–778.

    PubMed  CAS  Google Scholar 

  32. Sutton G, Axelrod JH, Bundy BN, et al.: Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2005, 97:755–763.

    PubMed  Article  Google Scholar 

  33. Homesley HD, Filiaci VL, Gibbons SK, et al.: Randomized phase III trial in advanced endometrial carcinoma of surgery and volume-directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study [abstract]. Presented at the 39th Annual Meeting of the Society of Gynecologic Oncologists. Tampa, FL; March 9, 2008. Gynecol Oncol 2008, 108:S1.

  34. Fleming GF, Brunetto VL, Cella D, et al.: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004, 22:2159–2166.

    PubMed  Article  CAS  Google Scholar 

  35. Levenback C, Burke TW, Silva E, et al.: Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992, 46:317–321.

    PubMed  Article  CAS  Google Scholar 

  36. Price FV, Chambers SK, Carcangiu ML, et al.: Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). Gynecol Oncol 1993, 51:383–389.

    PubMed  Article  CAS  Google Scholar 

  37. Ramondetta L, Burke TW, Levenback C, et al.: Treatment of uterine papillary serous carcinoma with paclitaxel. Gynecol Oncol 2001, 82:156–161.

    PubMed  Article  CAS  Google Scholar 

  38. Hoskins PJ, Swenerton KD, Pike JA, et al.: Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001, 19:4048–4053.

    PubMed  CAS  Google Scholar 

  39. Zanotti KM, Belinson JL, Kennedy AW, et al.: The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1999, 74:272–277.

    PubMed  Article  CAS  Google Scholar 

  40. Vaidya AP, Littell R, Krasner C, Duska LR: Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer 2006, 16(Suppl 1):267–272.

    PubMed  Article  Google Scholar 

  41. Chambers JT, Chambers SK, Kohorn EI, et al.: Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide. Gynecol Oncol 1996, 60:438–442.

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Blumenthal Cancer Center, Carolinas Medical Center, 1025 Morehead Medical Drive, Suite 600, Charlotte, NC, 28203, USA

    R. Wendel Naumann

Authors
  1. R. Wendel Naumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Wendel Naumann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Naumann, R.W. Uterine papillary serous carcinoma: State of the state. Curr Oncol Rep 10, 505–511 (2008). https://doi.org/10.1007/s11912-008-0076-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-008-0076-x

Keywords

  • Endometrial Cancer
  • Myometrial Invasion
  • Deep Myometrial Invasion
  • Gynecologic Oncology Group Study
  • Uterine Papillary Serous Carcinoma